SCHEMBL29964158

SCHEMBL29964158

CN(C)Cc1cc(-c2cc(-c3ccc4c(c3)CCNC4=O)c(N)nc2F)ccc1N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMARCA2 P51531 1/20 0.38
SMARCA4 P51532 1/20 0.38
PBRM1 Q86U86 1/20 0.38
GPR119 Q8TDV5 4/20 0.38
CDK4 P11802 1/20 0.37
CCND1 P24385 1/20 0.37
CCND3 P30281 1/20 0.37
CDK6 Q00534 1/20 0.37
ALOX5AP P20292 1/20 0.36
FEN1 P39748 1/20 0.36
PIM1 P11309 1/20 0.35
PIM2 Q9P1W9 1/20 0.35
BACE1 P56817 1/20 0.35
GSK3B P49841 1/20 0.34
MAPKAPK2 P49137 2/20 0.34
PARP1 P09874 1/20 0.34
MAPK1 P28482 1/20 0.34
PIK3CA P42336 2/20 0.34
MAP4K4 O95819 1/20 0.34
MTOR P42345 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29964810 0.92 SMARCA2 (0.37) SMARCA2SMARCA4PBRM1GPR119CDK4
SCHEMBL29964410 0.90 KDM1A (0.40) GPR119ALOX5APFEN1GSK3BPARP1
SCHEMBL29964373 0.88 SMARCA2 (0.41) SMARCA2SMARCA4PBRM1GPR119CDK4
SCHEMBL29964802 0.88 SMARCA2 (0.40) SMARCA2SMARCA4PBRM1GPR119CDK4
SCHEMBL29964997 0.87 RET (0.40) SMARCA2SMARCA4PBRM1GPR119CDK4
SCHEMBL29964506 0.86 CDK4 (0.42) CDK4CCND1CCND3CDK6GSK3B
SCHEMBL29964826 0.85 MAPK1 (0.45) CDK4CCND1CCND3CDK6MAPKAPK2
SCHEMBL29964517 0.85 MAPK1 (0.38) CDK4CCND1CCND3CDK6GSK3B
SCHEMBL31079216 0.84 MAPK1 (0.40) CDK4CCND1CCND3CDK6GSK3B
SCHEMBL29965135 0.84 MAPK1 (0.37) CDK4CCND1CCND3CDK6GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2024-10-17 US disclosed
WO-2022226668-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) CMPK1, WNK1, AAK1 SMARCA2 3906/4885SMARCA4 3351/4885PBRM1 1041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.